Tesamorelin + Ipamorelin Research Guide
Growth hormone secretagogue research stack
The Tesamorelin plus Ipamorelin blend pairs a GHRH analogue with a selective ghrelin receptor agonist into a single research preparation. The two compounds activate growth hormone release through mechanistically separate pathways, producing a substantially amplified GH pulse compared to either alone — without cortisol or prolactin elevation.
Contents
|
GHRH + ghrelin Dual receptor pathway |
10 mg + 5 mg Pre-blended ratio |
Selective No cortisol or prolactin rise |
What is Tesamorelin + Ipamorelin?
This blend contains 10 mg of Tesamorelin and 5 mg of Ipamorelin in a single lyophilized vial. Tesamorelin is a 44-amino-acid stabilized GHRH analogue, FDA-approved (2010) for HIV-associated lipodystrophy and the most clinically validated GHRH analogue in the catalog. Ipamorelin is a synthetic pentapeptide that selectively activates the ghrelin receptor (GHSR), producing GH release without the cortisol or prolactin elevation seen with earlier non-selective GHRPs.
The mechanistic rationale for combining them is straightforward. Tesamorelin’s GHRH receptor activation drives one pathway of GH release. Ipamorelin’s ghrelin receptor activation drives a parallel pathway. When both pathways are engaged simultaneously, the resulting GH pulse is 2-3 times larger than either compound produces alone, with the two mechanisms reinforcing rather than interfering with each other.
Aeternum Labs supplies this blend as a single-vial preparation. Both peptides are verified to 99%+ purity by HPLC with mass spectrometry sequence confirmation, with full Certificate of Analysis published in the public COA library.
Mechanism of action
Tesamorelin binds the GHRH receptor (GHRHR) on pituitary somatotropes, triggering cAMP elevation and vesicle release of stored growth hormone. The N-terminal trans-3-hexenoyl modification extends plasma half-life from native GHRH’s seconds to approximately 26 minutes, supporting practical daily dosing while maintaining a pulsatile GH release pattern.
Ipamorelin binds the growth hormone secretagogue receptor (GHSR, also called the ghrelin receptor), expressed on the same somatotropes. Receptor activation triggers a distinct intracellular pathway involving phospholipase C and IP3 that converges on the same outcome: GH vesicle release.
The synergy between the two pathways is the central feature of this blend. GHRH stimulation alone produces a moderate pulse. Ghrelin agonism alone produces a moderate pulse. Together, the combined pulse is much larger because each pathway sensitizes the somatotrope to the other’s signal. Researchers studying GH-axis pharmacology use this combination to maximize endogenous GH pulse amplitude.
Ipamorelin’s selectivity for GHSR (without significant affinity for the corticotrope receptor or prolactin-releasing pathways) is what distinguishes it from earlier GHRPs (GHRP-2, GHRP-6, hexarelin) that produce GH release alongside cortisol, prolactin, and appetite effects.
Research history
Tesamorelin’s development by Theratechnologies led to FDA approval in 2010 for HIV-associated lipodystrophy. The compound has the most extensive human safety database of any GHRH analogue, accumulated across the approved indication and subsequent research in MASLD, body composition, and cognitive aging.
Ipamorelin was characterized by Raun et al. (Novo Nordisk) in the late 1990s as the first GHRP with selectivity for GH release without parallel cortisol or prolactin elevation. This selectivity established Ipamorelin as the reference compound for clean GHRP research.
Combined-administration research using a GHRH analogue plus a selective GHRP emerged through the 2000s as a research strategy. The mechanistic synergy is well-documented across multiple published studies of pulse amplitude and IGF-1 elevation.
Half-life and pharmacokinetics
Tesamorelin has a plasma half-life of approximately 26 minutes after subcutaneous administration. Ipamorelin has a plasma half-life of approximately 2 hours. Combined administration produces overlapping activity windows where both pathways are simultaneously active.
Subcutaneous administration produces peak GH release within 30-60 minutes for the Tesamorelin component and a similar window for the Ipamorelin component. Daily IGF-1 elevation builds over 1-2 weeks of consistent administration, reaching steady-state by approximately day 14.
Pharmacokinetic note
The combined preparation simplifies dosing logistics. Rather than reconstituting and timing two separate vials, the blend produces parallel activity from a single injection.
Typical research doses
Combined research doses typically scale the two components together. A common starting protocol is 0.5 mL of the reconstituted blend (containing approximately 1 mg Tesamorelin + 0.5 mg Ipamorelin) per administration, given once or twice daily by subcutaneous injection.
Frequency in research designs is commonly twice daily, aligned with natural GH pulse timing — once before sleep (to align with the natural overnight GH pulse) and once in the morning or post-exercise. Some protocols use three-times-daily administration to maximize total GH exposure across a 24-hour cycle.
Compliance reminder
All dose ranges discussed are reported from peer-reviewed in vitro and animal research. They are not human-use dose recommendations.
Reconstitution protocol
Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.
Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.
Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.
For this blend, a vial containing 10 mg Tesamorelin + 5 mg Ipamorelin reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL Tesamorelin + 2.5 mg/mL Ipamorelin. Each 0.1 mL contains 0.5 mg Tesamorelin and 0.25 mg Ipamorelin.
Storage and stability
Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.
Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.
Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.
Common stack pairings
Tesa + Ipa + Retatrutide (metabolic + body composition research)
Layering Retatrutide’s triple-incretin metabolic mechanism on top of GH-axis activation captures both fat-mass reduction (Retatrutide) and visceral-fat-specific effects (Tesamorelin), plus the GH-mediated lean mass effects from the full secretagogue stack.
Tesa + Ipa + BPC-157 (recovery research)
GH-axis stimulation supports systemic IGF-1 elevation while BPC-157 provides local tissue repair effects through VEGF and nitric oxide synthase pathways. The combination targets recovery endpoints across systemic and local tissue levels.
How it compares
Compared to Tesamorelin alone: adding Ipamorelin engages the parallel ghrelin pathway, producing a 2-3x larger GH pulse. Standalone Tesamorelin produces a moderate single-pathway pulse.
Compared to CJC-1295 + Ipamorelin (the other dual-pathway GHRH+GHRP combination): Tesamorelin has the more extensive clinical data and FDA approval. CJC-1295 has a shorter half-life (30 min vs 26 min for Tesa) but is less clinically validated.
Compared to exogenous GH administration: the secretagogue stack produces pulsatile endogenous GH release that respects natural negative feedback. Exogenous GH produces sustained levels that override feedback mechanisms. Different research contexts favor different patterns.
From the Aeternum library
Tesamorelin + Ipamorelin Blend (10 mg + 5 mg)
- 10 mg Tesamorelin + 5 mg Ipamorelin per vial
- 99%+ purity verified for both compounds
- Mass spec sequence confirmation
- LAL endotoxin screening
- Full Certificate of Analysis published
Frequently asked questions
Why combine Tesamorelin and Ipamorelin?
The two peptides act on different receptors (GHRH receptor and ghrelin receptor) that both trigger GH release through distinct intracellular pathways. Combined, they produce a GH pulse 2-3 times larger than either alone — a synergistic effect that is the main rationale for the blend.
How does this blend differ from CJC-1295 + Ipamorelin?
Both blends pair a GHRH analogue with Ipamorelin. The Tesamorelin variant uses the FDA-approved compound with the most clinical data. The CJC-1295 No DAC variant uses a research compound with a slightly different half-life (30 min vs 26 min). For clinical-adjacent research, Tesamorelin is the more validated choice.
Will this combination raise cortisol?
No. Ipamorelin’s selectivity for the ghrelin receptor means it produces GH release without significantly elevating cortisol or prolactin. Tesamorelin acts through the GHRH receptor, which also does not elevate cortisol. The combination is specifically designed for clean GH-axis activation.
What dose ranges are used in research?
Most published research uses 0.5-1 mL of the reconstituted blend per administration (containing 1-2 mg Tesamorelin + 0.5-1 mg Ipamorelin), given subcutaneously 1-3 times daily. Frequency is typically aligned with natural GH pulse timing.
How is the blend reconstituted?
Standard peptide reconstitution applies: bacteriostatic water added slowly down the inside wall of the vial, gentle swirl until both peptides dissolve into a clear solution. Both peptides are stable in bacteriostatic water for the standard twenty-eight days under refrigeration.
References
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. View source
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. View source
- Sigalos JT, Pastuszak AW (2018). The Safety and Efficacy of Growth Hormone Secretagogues. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Articles in our research blog summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry and laboratory protocol design.
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.